

Viewpoint

Extreme growth factor signalling can promote oestrogen receptor- α loss: therapeutic implications in breast cancer

Julia MW Gee, Martin G Giles and Robert I Nicholson

Tenovus Centre for Cancer Research, Welsh School of Pharmacy, Cardiff University, CF10 3XF, Wales, UK

Corresponding author: JMW Gee, gee@cardiff.ac.uk

Published: 9 June 2004

Breast Cancer Res 2004, **6**:162-163 (DOI 10.1186/bcr904)

© 2004 BioMed Central Ltd

Introduction

Most breast cancers overexpress the oestrogen receptor (ER)- α , and the ER α + phenotype is relatively stable during endocrine treatment and on subsequent treatment failure. However, approximately 30% of tumours are ER α - at diagnosis, while a proportion of tumours, which are initially ER α +, lack the receptor at the time of tamoxifen relapse in the adjuvant or metastatic setting. The mechanisms underlying *de novo* and acquired ER α negativity remain poorly-defined, although their elucidation is of obvious therapeutic interest since the ER α - phenotype is associated with endocrine resistance, aggressive tumour biology and poor prognosis. Somatic mutations in the ER α gene are quite rare and are therefore unlikely to explain the frequency of ER α negativity. Epigenetic mechanisms, notably CpG island methylation and histone deacetylation, may contribute by silencing ER α gene transcription in approximately 25% of *de novo* ER α - cancers [1]. Interestingly, ER α expression and function can be partially recovered in ER α - models using the DNA methyl transferase (DNMT) inhibitor aza-2-deoxycytidine, DNMT1 antisense, or the histone deacetylase inhibitor trichostatin [2]. However, there is also emerging evidence that sustained, exaggerated growth factor pathways [notably those hyperactivating extracellular signal-regulated kinases (ERK)1/2 mitogen activated protein kinase (MAPK)] may promote substantial decline, and even total loss, of ER α . A new article by Holloway and colleagues [3] sheds light on this mechanism of ER α negativity, revealing that exaggerated ERK1/2 MAPK signalling promotes ER α downregulation via its impact on cytoplasmic substrates that include the transcription factor nuclear factor kappa B (NF κ B).

Hyperactivation of ERK1/2 MAPK promotes oestrogen receptor loss via cytoplasmic substrates including NF κ B

Growth factor pathways can enhance ER α phosphorylation, transcriptional activity and cell growth in the absence of ER α ligand. Paradoxically, a decline in ER α expression may also be a possible outcome when growth factor signalling is extreme, reminiscent of the ER α downregulation that occurs during chronic receptor activation by oestrogen [4]. Supportive evidence are drawn from stable transfection studies where growth factor signalling elements, notably those comprising the epidermal growth factor receptor (EGFR)/HER2 pathway, promote ER α loss when overexpressed in ER α + breast cancer cells. Oh and colleagues noted precipitous decreases in ER α mRNA and protein in MCF-7 cells transfected with constitutively active HER2, mitogen activated kinase kinase 1 (MEK1), Raf-1 kinase (Raf1) or ligand-activatable EGFR, all of which hyperactivate ERK1/2 MAPK [5]. They also noted a loss of oestrogen-mediated gene expression and oestrogen response element (ERE) activity, and acquisition of endocrine resistance. Interestingly, the phenomenon was reversible, since abrogation of hyperactivated ERK1/2 MAPK restored ER α expression and activity. Extending these studies, Holloway and colleagues have now begun to decipher the mechanism of MAPK-mediated ER α loss in these various transfected models. Using dominant negative constructs, they show that hyperactivated ERK1/2 MAPK downregulate ER α via a common substrate. Use of an ERK2 deletion construct to prevent nuclear MAPK activity reveals this substrate is cytoplasmic. By examining potential MAPK substrates

DNMT = DNA methyl transferase, EGFR = epidermal growth factor receptor, ER = oestrogen receptor; ERK = extracellular signal regulated kinase, MAPK = mitogen activated protein kinase, STI = signal transduction inhibitor.

(again using appropriate dominant negatives), they demonstrate that activator protein-1 (AP-1) and 90 kDa ribosomal S6 kinase 1 (RSK1) are not responsible for the ER downregulation promoted by MAPK hyperactivation. However, there does appear to be some importance for NFκB. This growth-promoting transcription factor can be cytoplasmically-activated (prior to its nuclear translocation) via MAPK-mediated induction of autocrine growth factors (e.g. heparin-binding EGF). Holloway and colleagues demonstrate gross elevation of NFκB activity in the various models exhibiting MAPK hyperactivation. This NFκB activity is inhibited by abrogating ERK1/2 MAPK signalling. Importantly, blockade of NFκB activity (e.g. using Parthenolide) restores ERα expression and activity in parallel, although interestingly there was only partial recovery indicating existence of additional cytoplasmic substrates.

Conclusions

These new data obtained by Holloway and colleagues in stable transfected cells are important in that they provide proof of principle that extreme growth factor signalling, resulting in ERK1/2 MAPK hyperactivation and recruitment of cytoplasmic substrates including NFκB, is capable of promoting ERα loss. Further molecular detail of the receptor downregulation mechanism, determination of growth factor signalling thresholds required to instigate ERα loss, and the impact of hyperactivation of additional signalling cascades (e.g. phosphatidylinositol 3' kinase [6]) is now required. Questions clearly remain regarding relevance to ERα negativity *de novo* or acquired during therapy. Significant, however, is the inverse ERα/EGFR association in clinical disease and elevated ERK1/2 MAPK and NFκB signalling observed in ERα- cells [7,8]. Moreover, ERα transrepresses proinvasive genes and so growth factor-mediated ERα loss may underlie poor prognosis in ERα negative disease [6]. Finally, modestly increased growth factor signalling activates ERα in acquired tamoxifen resistance, explaining subsequent antihormone response; however, more extreme/prolonged signalling might promote ERα negative endocrine insensitivity in some patients during sequential endocrine challenge [7].

While future studies are clearly required, the data from Holloway and colleagues do have exciting ramifications for possible therapeutic approaches in ERα- disease. Manipulation of growth factor pathways (in particular ERK1/2 MAPK and potentially NFκB signalling) with signal transduction inhibitors (STIs) might feasibly recover ERα positivity in ERα- cells, hence restoring sensitivity to antioestrogen if used in combination. Importantly, the group demonstrate that *in vitro* pharmacological or dominant negative blockade of ERK1/2 MAPK signalling does re-instate physiological levels of ERα expression and function in their stable-transfected cells. Of course, we

must await future experimental consolidation and appropriate clinical examination, but a compelling preliminary study demonstrates that reversion of ERα negativity and re-instatement of endocrine responsiveness occurs in a proportion of advanced HER2+ breast cancer patients using Herceptin to inhibit growth factor signalling [9]. Since this mechanism may only be applicable in tumours without epigenetic ERα silencing, combination therapy of STIs plus appropriate strategies to abrogate ER methylation/deacetylation could prove worthy of future exploration. However, DNMT1 can be growth factor-regulated and so perhaps sustained increases in growth factor signalling ultimately culminate in ERα promoter silencing. If so, STIs might also prove effective in restoring ERα where there is ERα promoter hypermethylation. Intriguingly, pharmacological inhibition of Ras signalling does reverse gene methylation events in other cancer models via downregulating DNMT1 [10].

Competing interests

The authors are in receipt of research grants funded by AstraZeneca and Merck KGaA.

References

1. Parl FF: **Multiple mechanisms of estrogen receptor gene repression contribute to ER-negative breast cancer.** *Pharmacogenomics J* 2003, **3**:251-253.
2. Yan L, Nass SJ, Smith D, Nelson WG, Herman JG, Davidson NE: **Specific inhibition of DNMT1 by antisense oligonucleotides induces re-expression of estrogen receptor-alpha (ER) in ER-negative human breast cancer cell lines.** *Cancer Biol Ther* 2003, **2**:552-556.
3. Holloway JN, Murthy S, El-Ashry D: **A cytoplasmic substrate of MAPK is responsible for ERα downregulation in breast cancer cells: the role of NFκB.** *Mol Endocrinol* 2004, **18**:1396-1410 [Epub 2004 Mar 31].
4. Stoica GE, Franke TF, Wellstein A, Morgan E, Czubyko F, List HJ, Reiter R, Martin MB, Stoica A: **Heregulin-β1 regulates the estrogen receptor-alpha gene expression and activity via the ErbB2/PI 3-K/Akt pathway.** *Oncogene* 2003, **10**:2073-2087.
5. Oh AS, Lorant LA, Holloway JN, Miller DL, Kern FG, El-Ashry D: **Hyperactivation of MAPK induces loss of ERα expression in breast cancer cells.** *Mol Endocrinol* 2001, **15**:1344-2359.
6. Bhat-Nakshatri P, Campbell RA, Patel NM, Newton TR, King AJ, Marshall MS, Ali S, Nakshatri H: **Tumour necrosis factor and PI3-kinase control oestrogen receptor alpha protein level and its transrepression function.** *Br J Cancer* 2004, **90**:853-859.
7. Nicholson RI, Hutcheson IR, Knowlden JM, Jones HE, Harper ME, Jordan N, Hiscox SE, Barrow D, Gee JM: **Non-endocrine pathways and endocrine resistance: observations with antiestrogens and signal transduction inhibitors in combination.** *Clin Cancer Res* 2004, **10**:346S-354S.
8. Nakshatri H, Bhat-Nakshatri P, Martin DA, Goulet RJ, Jr., Sledge GW, Jr.: **Constitutive activation of NF-kappaB during progression of breast cancer to hormone-independent growth.** *Mol Cell Biol* 1997, **17**:3629-3639.
9. Munzone E, Nole F, Renne G, Balduzzi A, Sanna G, Corsetto L, Goldhirsch A: **Reverting estrogen receptor (ER) negative phenotype in advanced breast cancer patients over-expressing HER2 after treatment with trastuzumab plus chemotherapy.** *Proc Am Soc Clin Oncol* 2003, **22**:848 [Abstract 3409].
10. Alcock RA, Dey S, Chendil D, Inayat MS, Mohiuddin M, Hartman G, Chatfield LK, Gallicchio VS, Ahmed MM: **Farnesyltransferase inhibitor (L-744,832) restores TGF-beta type II receptor expression and enhances radiation sensitivity in K-ras mutant pancreatic cancer cell line MIA PaCa-2.** *Oncogene* 2002, **21**: 7883-7890.